News ArchivesRead News

Your Parkinson's News Update for the Week of 9/7/20

Monday September 07, 2020
Deep Brain Stimulation in Parkinson's Disease Market
Worth USD 2.16 Billion by 2028
The global deep brain stimulation in Parkinson’s disease market is expected to reach at USD 2.16 billion by 2028 with a CAGR of 9.6%, according to a new report by Grand View Research. The rise in prevalence of neurological disease and increase in preference for targeted therapy is driving the market growth for deep brain stimulation devices for Parkinson’s. The market growth is nurtured owing to the potential benefits of deep brain stimulation devices and postoperative outcomes. These advancements enable clinical researchers for investigative studies. Therefore, immense research, clinical studies and the need for efficient clinical data is likely to trigger the market growth.
Berwyn Biopharm Firm Begins Mid-stage Testing of Experimental Therapy for Alzheimer's, Parkinson's
Philadelphia Business Journal
The study will compare, in both patient populations, how nerve cells die by measuring all the steps in the "toxic cascade" leading to nerve cell death — and how Annovis' experimental treatment, ANVS401, might reverse the toxic cascade and recover normal brain function.
The clinical trial will also look at safety and tolerability, and the effect of ANVS401 on motor and non-motor symptoms in early Parkinson's patients and the effect on memory and cognitive function in early Alzheimer's patients.
Mediterranean Diet May Lower Parkinson’s Risk
Harvard Medical School
This is the source article that follows up with previous newsletter's reporting of the study:
Researchers looked at health data from 47,679 participants in the Nurses’ Health Study and the Health Professionals Follow-up Study. They compared participants’ diets to a Mediterranean-style diet and also scored what they ate using the Alternate Healthy Eating Index.